PD-1 cancer vaccine development update
MELBOURNE Australia 23 July 2018: Imugene Limited (ASX: IMU), a clinical stage immunooncology company is pleased to announce a development update of its newly acquired PD-1 cancer vaccine from Ohio State University. The check-point inhibitor cancer vaccine named KEY-Vaxx, demonstrates superior cancer growth inhibition compared with an industry-standard monoclonal antibody in validated models of colorectal (colon) cancer (CT26).
New PD-1 cancer vaccine named KEY-Vaxx
Phase 1 planning well advanced
Preclinical results in validated models of colorectal (colon) cancer demonstrate inhibitory cancer growth activity
For further information please download PDF attached:
Download this document